Brian joined LabCorp in September 2017 to serve as Chief Medical Officer for the enterprise. As CMO, he helps drive our company’s clinical strategies around health policy and regulatory efforts, value-based care models and clinical standards of care in our changing health care payment landscape. Prior to joining LabCorp, Brian served a variety of roles at Blue Cross & Blue Shield of North Carolina, including Chief Medical Officer. He was responsible for healthcare program strategy, care management, network provider contracting, medical coverage policy, medical expense initiatives, care quality and pharmacy. Read his full bio.

Interview with Brian Caveney from LabCorp

Q: What need is LabCorp addressing?

A: The timeless issues LabCorp continues to address are those related to delivering world-class diagnostics solutions, bringing innovative medicines to patients faster and using technology to improve the delivery of healthcare. Our innovations help to shorten clinical trial times and expand therapeutic options and diagnostics for doctors, positively affecting quality and cost.

Q: What are the products and/or services LabCorp offers/develops to address this need? What makes LabCorp unique?

A: LabCorp understands that one size does not always fit all, as the future of healthcare is personal. By bringing together world-class diagnostics through LabCorp Diagnostics and end-to-end drug development capabilities through Covance Drug Development, LabCorp is uniquely positioned at the intersection of research and patient care to enable more precise and individualized healthcare.

Q: What is your role at LabCorp and what excites you about your work?

A: Every day, I am amazed and impressed by the high level of scientific talent that we have across LabCorp Diagnostics and Covance Drug Development; the level of commitment that employees have to our mission of improving health and improving lives; and our ability to deliver world-class solutions to doctors and patients navigating the increasingly complex healthcare system.

Much of my focus is on our three strategic initiatives: value-based care, consumer engagement and streamlining drug development. LabCorp has chosen to focus on these initiatives because they are the areas where we can bring the most value. More specifically, we are addressing the empowerment of consumers in managing their own healthcare, and exploring how we can use diagnostics to improve healthcare decision-making and control costs. Another area where we can make a big difference is in helping our clients bring medicines to market faster by addressing the time and complexity of clinical trials and patient recruitment.

Q: When thinking about LabCorp and the domain LabCorp is working in, what are some of the recent breakthroughs that are propelling the field forward and how will they impact healthcare?

A: LabCorp’s broad portfolio of tests includes many options — from companion diagnostics and pharmacogenetics to genomics and therapeutic drug monitoring — that can help providers identify the right drug, at the right dose, for the right patient.

The majority of drug therapies in development today are driven by biomarkers, or laboratory assays that can indicate whether patients have a particular condition or disease state. These biomarker-driven efforts are what can lead to the development of the appropriate companion diagnostic assays, or in certain situations, a complementary diagnostic. LabCorp is the market leader for the development, validation, and commercialization of companion diagnostics, which are key drivers of personalized medicine.

Additionally, biologics are the fastest-growing drug class and make up more than one-third of the pharmaceutical pipeline. Biologic drugs—which are used to treat many different diseases and conditions, such as Crohn’s disease, rheumatoid arthritis and multiple sclerosis—can not only be expensive, but also highly variable in effectiveness from patient to patient. Therapeutic drug monitoring (TDM) is an area of growth in precision medicine due to increased demand for better treatment outcomes and minimum side effects. TDM is known to promote better patient outcomes and cost savings for payers. One study found a cost savings of 28 to 34 percent through the use of some TDM tests. LabCorp offers the most comprehensive offerings of TDM tests available for many of the highest-grossing prescription drugs on the market.

Q: What are the short-term challenges that LabCorp and its peers are facing?

A: As always, there are a myriad of trends and challenges on the horizon, particularly as our industry experiences rapid changes. As healthcare regulatory and payment systems transform, and the industry experiences cuts to government funding, we continue to innovate our business to address needs for the customer segments we serve across the healthcare continuum, from consumers and physicians to managed care partners and biopharmaceutical companies.

Q: Is there anything else you would like to share with the PMWC audience?

A: Collectively, we need to continue building a solid evidence base for the appropriate use of advanced diagnostics that can help improve clinical outcomes, reduce medication errors, and impact the total cost of care. If we can demonstrate those attributes, precision medicine will flourish in the future.

Interview with Daniel Chen from IGM Biosciences

Q: Checkpoint inhibitors, particularly with PD-L1/PD-1 targeting agents, have benefited a broad range of patients with cancer. How will we improve on this?

A: It’s true that PD-L1/PD-1 inhibitors have led to durable responses in a subset of patients, and survival benefit in many of the patients treated- either as monotherapy or combination.

Read More

Call from PMWC 2019 Silicon Valley Program Committee – We Must Accelerate and Deliver on the Promise of Precision Medicine

Precision medicine advancements are real as demonstrated by the high volume of molecular, “precise” drugs on the market, which are based on extensive molecular and translational understanding of the specific drug targets.

Read More

#AI Play in Patient Diagnosis? How Can We Prepare the Next Generation to Make Sense of Enormous Amounts of Health-related Data?

What role should artificial intelligence play in patient diagnosis? How can we best prepare the next generation to make sense of enormous amounts of health-related data? These were just a few of the questions explored at the 15th Precision Medicine World Conference held at Duke University September 24-25, 2018.

Read More

Interview with Daniella Beller, Manager, Maccabi Research Institute Biobank

Q: What makes the Maccabi Research Institute biobank unique?

A: To explain the uniqueness of the Maccabi Biobank (named “Tipa” in Hebrew which means “drop” or “just a little”), first you must know a little about Maccabi.

Read More

Why We Need Public-Private Partnerships (PPP) To Foster Drug Discovery

Investments in pharma R&D has substantially increased over the last decades. Yet there appears to be no clear correlation to the number of newly approved drugs. This fact is accompanied by ever-increasing healthcare costs, fueled by an aging population and the parallel rise in the chronic disease burden.

Read More

Precision Medicine: A Decade of Improving the Standard of Care

In January, PMWC will host its 2019 Silicon Valley event, the largest Precision Medicine conference in the world with over 2,500 attendees gathering at the Santa Clara Convention Center. We are humbled and honored to have reached this stage of growth and are looking forward to continuing our work with key stakeholders and decision makers across the industry to ever strengthen this forum for exchange of critical and timely topics, to move the field of precision medicine forward and to improve the Standard of Care.

Read More

Interview with David Hong from Karius

Q: What need is Karius addressing?

A: Physicians often have difficulty pinpointing the exact pathogen that is causing disease. Conventional diagnostics like blood cultures or PCR can have poor sensitivity due to pretreatment with antibiotics, the breadth of potential pathogens present, and the requirement for invasive procedures to access deep-seated infections.

Read More

Interview with Charles Jaffe, MD, PhD from HL7

Q: What need is HL7 addressing?

A: For more than three decades, HL7 has provided the platform to enable global health data interoperability. This is more important than ever, as the cost of healthcare has increased exponentially, and the complexity of clinical evidence has grown to an almost unmanageable state.

Read More

Interview with Eden Haverfield from Invitae

Q: What need is Invitae addressing?

A: Our mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae is uniquely positioned to answer some of life’s most serious and complex questions with the highest quality genetics and at an affordable price.

Read More

Call by Ralph Snyderman (Duke U.) for Big Changes to Get to the Next Level of Precision Medicine

Beyond next-generation gene sequencing and developing diagnostic tools and targeted therapies, theoverall approach to clinical care has to be re-envisioned to fulfill the promise of precision medicine. Care must move from sporadic treatment of episodic disease (a reactive mode) to predicting disease and then acting to prevent and mitigate it (a proactive mode).

Read More

Interview with William Hearl From Immunomic Therapeutics, Inc.

Q: What need is Immunomic Therapeutics, Inc. addressing?

A: Immunomic Therapeutics’ nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response, including antibody production, cytokine release and critical immunological memory.

Read More

Interview with Ralph Snyderman from Duke University

Q: What are some of the critical contributions that academic institutions and medical centers are making to implement and accelerate precision medicine?

A: Over the past decade, the field of precision medicine has created technologies enabling far more personalized and effective health care delivery. Many of the most dramatic advances have come in the field of oncology but targeting care to the needs of the individual is rapidly achieving broader applications.

Read More

Interview with Catherine Reinis Lucey from UCSF

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Gunnar Carlsson from Ayasdi

Q: What need is Ayasdi addressing?

A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Interview with Nikole Kimes from Siolta Therapeutics

Q: What need is Siolta Therapeutics addressing?

A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 16th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 20-23, 2019. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!
pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!